Genfit Sa · EURONEXT:GNFT
Genfit Sa — Shareholder Meeting (June 2020)
28 slides from Genfit Sa's shareholder meeting presentation, Jun 11, 2020
Slide 1: Annual General Meeting presentation and verbatim
Annual General Meeting presentation and verbatim (English) June 11, 2020
Slide 2: Disclaimer
Disclaimer IMPORTANT NOTICE – YOU MUST READ THE FOLLOWING BEFORE CONTINUING. THIS PRESENTATION HAS BEEN PREPARED BY GENFIT AND IS FOR INFORMATION PURPOSES ONLY. CERTAIN OF THE INFORMATION CONTAINED HEREIN CONCERNING ECONOMIC TRENDS AND PERFORMANCE IS BASED UPON OR DERIVED FROM INFORMATION PROVIDED B
Slide 3: Annual Shareholders Meeting - Forward Looking Statement
Jean-François Mouney, Chairman of the Board of Directors of GENFIT Forward Looking Statement IMPORTANT NOTICE – YOU MUST READ THE FOLLOWING BEFORE CONTINUING. THIS PRESENTATION HAS BEEN PREPARED BY GENFIT AND IS FOR INFORMATION PURPOSES ONLY. CERTAIN OF THE INFORMATION CONTAINED HEREIN CONCERNING EC
Slide 4: Convening Notice and Shareholders Meeting Committee
Jean-François Mouney, Chairman of the Board of Directors of GENFIT Shareholders Meeting Committee Convening Notice (Bureau de l’Assemblée Générale) • Ladies and Gentlemen, GENFIT’s (The Company) shareholders are convened to the • Chairman: Mr. Jean-François Mouney, Chairman of the Board of Directors
Slide 5: Table of Contents and Quorum
Jean-François Mouney, Chairman of the Board of Directors of GENFIT Quorum Table of Contents 1. Global Corporate Update: a) 2019 Key highlights b) Key Highlights since year end c) Company situation and future perspectives 18.08% d) 2019 Financial Results e) Statutory Auditors’ reports f) Use of autho
Slide 6: Global Corporate Update
Pascal Prigent, Chief Executive Officer of GENFIT 1. Global Corporate Update Thank you Jean-François, and good morning everyone. Before we address the 2019 key highlights, I want to acknowledge the many questions received following the release of RESOLVE-IT data on May 11, either via emails from ret
Slide 7: 2019 Key Highlights (1/3): Clinical and regulatory milestones
Pascal Prigent, Chief Executive Officer of GENFIT 2019 Key Highlights(1/3) We will begin by taking a retrospective look at the 2019 key highlights. For those of you who Clinical and regulatory milestones follow the company closely, there will be limited new information, but a Shareholders meeting is
Slide 8: 2019 Highlights (2/3): Commercial milestones, governance
Pascal Prigent, Chief Executive Officer of GENFIT Now, we move on to commercial milestones. The past year was marked by two significant deals. Significant because they have demonstrated the Company’s ability to value its assets through strategic partnerships. • In January 2019, GENFIT made a great s
Slide 9: 2019 Key Highlights (3/3): Financial, Nasdaq IPO
Pascal Prigent, Chief Executive Officer of GENFIT 2019 Key Highlights (3/3) Financial • IPO on the Nasdaq Global Select Market › In March 2019 › Global offering of American Depositary Shares (ADSs) in the United States and associated capital fundraise in Europe and other countries (excluding the Uni
Slide 10: Key highlights since year end (1/4)
Pascal Prigent, Chief Executive Officer of GENFIT 1. Global Corporate Update Now we will shift to more recent highlights, which will be of greater interest for the attendees listening to this virtual Shareholders Meeting, whom I would like to thank for their participation today. 2020 has had a compl
Slide 11: Key Highlights since year end (2/4): RESOLVE-IT top-line data
Pascal Prigent, Chief Executive Officer of GENFIT Returning to the main milestone from the past few weeks, I will now focus on our Phase 3 clinical trial results in NASH. Since the interim outcome of the clinical trial was recently announced and discussed in various presentations (press releases, we
Slide 12: Key Highlights since year end (3/4): RESOLVE-IT data
Pascal Prigent, Chief Executive Officer of GENFIT As we move on to the next slide, I’ll start with a short comment, to answer a question that we have received from a few investors regarding the timing of the data publication: “Why didn’t you hold the data release so you could have more time to evalu
Slide 13: Key highlights since year end (4/4): Drug development process
Pascal Prigent, Chief Executive Officer of GENFIT Key highlights since year end (4/4) The table you can see on this slide comes from the “Office of Health Economics” in the U.K, and Reminder on the new drug development process similar data are published by the LEEM in France or PhARMA in the U.S. Th
Slide 14: Company situation and future perspectives (1/3): R&D pipeline
Pascal Prigent, Chief Executive Officer of GENFIT 1. Global Corporate Update c) Company situation and future perspectives I won’t spend too much time on this slide as it’s only an update of our pipeline, especially because it’s included with other details in the URD and 20-F that we recently publish
Slide 15: Company situation and future perspectives (2/3)
Pascal Prigent, Chief Executive Officer of GENFIT I’ll move to the most interesting elements of this presentation, those that have to do with the implications of the RESOLVE-IT interim data for the future of GENFIT. The action plan that has been put together for the weeks and months to come is struc
Slide 16: Action plan prior to new corporate strategy definition
Pascal Prigent, Chief Executive Officer of GENFIT because the activity demonstrated in the Phase 2 was very clear, and the molecule’s safety profile was confirmed by the RESOLVE-IT data. We believe elafibranor still has a real potential in this indication. So for all of you wondering about the poten
Slide 17: Company situation and future perspectives (3/3): Implications and implementation
Pascal Prigent, Chief Executive Officer of GENFIT The outcome of these 3 priorities will have implications on two levels: • GENFIT has enacted a significant plan for cost reduction following the May 11 announcement, with immediate measures including the termination of marketing and commercialization
Slide 18: 2019 Financial results: Key Figures (Consolidated)
Nathalie Huitorel, Chief Financial Officer of GENFIT Key Figures (Consolidated) 1. Global Corporate Update IFRS –2019/12/31 d) 2019 Financial results June 11, 2020 - Shareholders Meeting 20 June 11, 2020 - Shareholders Meeting 21 Annual General Meeting - June 11, 2020 18
Slide 19: Consolidated Statement of Financial Position
Nathalie Huitorel, Chief Financial Officer of GENFIT Consolidated Statement of Financial Position Consolidated Statement of Financial Position Assets - IFRS – 2019/12/31 Liabilities - IFRS – 2019/12/31 June 11, 2020 - Shareholders Meeting 22 June 11, 2020 - Shareholders Meeting 23 Annual General Mee
Slide 20: Statutory Auditor's reports
Jean-François Baloteaud, representing Grant Thornton Company 1. Global Corporate Update Statutory Auditor’s reports • Statutory Auditor’s reports on consolidated financial statement for the year ended december 31, 2019 • Statutory Auditor’s reports on consolidated financial statements for the year e
Slide 21: Use of authorisations granted by the Shareholders meeting
Jean-François Mouney, Chairman of the Board of Directors of GENFIT Use of authorisations granted by the Shareholders meeting 1. Global Corporate Update 2019 use of authorisations granted by the combined Shareholders Meeting of June 15, 2018 • March 2019 : Use of authorisations granted by the resolut
Slide 22: Use of authorisations - Shareholders Meeting of November 27, 2019
Jean-François Mouney, Chairman of the Board of Directors of GENFIT Use of authorisations granted by the Shareholders meeting 2019 use of authorisations granted by the Shareholders Meeting of November 27, 2019 • November 2019 : use of authorisations granted by Resolution n°8 to allocate stock options
Slide 23: 2019 Compensation – Corporate Officers
Xavier Guille des Buttes, Vice-Chairman of the Board of Directors of GENFIT Company Compensation Policy 2. Company Compensation Policy 2019 Compensation – Corporate Officers (1/2) 2019 Compensation – Corporate Officers (2/2) June 11, 2020 - Shareholders Meeting 29 June 11, 2020 - Shareholders Meetin
Slide 24: 2019 Compensation – CEO and Chairman
Xavier Guille des Buttes, Vice-Chairman of the Board of Directors of GENFIT 2. Company Compensation Policy 2. Company Compensation Policy 2019 Compensation – CEO and Chairman of the Board of Directors until 09/15 2019 Compensation – Chairman of the Board of Directors between 09/16 and 12/31 • Fixed
Slide 25: 2019 Compensation – CEO; 2020 Compensation unchanged
Xavier Guille des Buttes, Vice-Chairman of the Board of Directors of GENFIT 2. Company Compensation Policy 2. Company Compensation Policy 2019 Compensation – CEO between 09/16 and 2019/31/12 2020 Compensation (unchanged) – Corporate Officers • Fixed compensation: 94.694€ • No annual variable compens
Slide 26: 2020 Compensation – Chairman and CEO (Summary)
Xavier Guille des Buttes, Vice-Chairman of the Board of Directors of GENFIT 2. Company Compensation Policy 2. Compensation Policy 2020 Compensation – Chairman of the Board of Directors (Summary) 2020 Compensation – CEO (Summary) • Annual gross fixed compensation (unchanged) : 192.996€ • Gross annual
Slide 27: Appointment of new Directors
Xavier Guille des Buttes, Vice-Chairman of the Board of Directors of GENFIT 3. Appointment of new Directors 3. Appointment of new directors Mme Katherine KALIN - Application Mr. Eric Baclet - Application June 11, 2020 - Shareholders Meeting 37 June 11, 2020 - Shareholders Meeting 38 Annual General M
Slide 28: End & Lexicon
End & Lexicon 20F: Annual Report Form 20-F AMF: Autorité des Marchés Financiers (France) CRO: Contract Research Organization DSMB: Data Safety Monitoring Board EASL ILC: International Liver Congress of European Association for the study of the liver MERCI THANK YOU EMA: European Medicines Agency FDA